![](/wp-content/uploads/2023/10/Screenshot-2023-10-27-at-1.31.55-PM.png)
$599
Sanofi Q3 ’23 Earnings; Additional Sernova Cell Pouch Data; GSK Initiates New Ph2a NASH Study
Three cardiometabolic-related news items have been observed: Sanofi hosted its Q3 ’23 earnings call (press release; slides; infographic); Sernova announced positive interim results from its ongoing Ph1/2 Cell Pouch study (view press release); and GSK initiated a new Ph2 study evaluating GSK4532990 in participants with NASH and suspected NASH (view CT.gov record). Below, FENIX provides highlights and insights into the respective news items.